A range of vaccine approaches are being tested in early phase clinical trials. This table provides highlights of this area of vaccine research.
Additional Vaccine Approaches
Neutralizing Antibodies
This graphic explains on how neutralizing antibodies work, provides research background and gives an advocates’ checklist for what to look for going forward.
Vaccine Research Developing Programs
This graphic provides a state of the field on vaccine research development programs, giving details on the Pox-Protein Public-Private Partnership trials testing canarypox-protein based vaccine candidates and the Jannssen development program of Ad26 vector + Mosaic immunogen vaccine strategy.
AIDS Vaccine Science: Hot Seat
This is training exercise designed to bring HIV vaccine research information to life.
After FACTS: What’s next for HIV prevention in women?
FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. In this webinar, we discussed what these and other data meant for women, including young and adolescent girls.
Selected Guide to Pipeline of Antibodies, Long-Acting ARVs and Vaccines
This graphic provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Success with PrEP: Next Steps to Support Policy Decisions in Southern and East Africa
Convened on 26 October 2014 by AVAC, UNAIDS and WHO, this meeting brought together representatives of ministries of health and national AIDS councils, PrEP researchers and participants from research and demonstration sites where PrEP is currently being delivered in Kenya, Mozambique, South Africa, Uganda and Zimbabwe, along with funders, manufacturers and HIV advocates and activists. Through a series of presentations, moderated discussions and small group work, participants shared current experiences and helped define a structured approach to considering the integration of PrEP in HIV prevention programs in the region. In addition, some of the knowledge gaps that remain to be researched were identified.
Px Wire April-June 2015, Vol. 8, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, you’ll find updates and how WHO is approaching broader guidance on oral PrEP and a closer look at passive immunization.
Our centerspread provides a quick primer on passive immunization with HIV-specific antibodies, long-acting antiretroviral injectables, and preventive vaccines, including a new, informative table reviewing the pipelines in research and development for all three research avenues.
Proceedings from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants.
Slides from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants. All slide presentations from the workshop are included.